GTBP - GT Biopharma and Cytovance Biologics announces milestone achievement

GT Biopharma ([[GTBP]] +1.8%) issued $1M of restricted common stock to Cytovance; number of shares was based on the closing price of $0.31 as on December 15, 2020."We are pleased to have the opportunity to work with Cytovance and their experienced team for the GMP manufacture of our TriKE product candidates. Achievement of the subject Milestone was achieved on-time and on-budget by Cytovance and we believe our partnership and their acceptance of our company stock illustrates their commitment to us and this partnership for the long term,” commented Anthony Cataldo, Chairman and CEO of of GT Biopharma.Previously: GT Biopharma inks partnership agreement with Cytovance Biologics (Oct. 6)

For further details see:

GT Biopharma and Cytovance Biologics announces milestone achievement